Search clinical trials for: pneumococcal conjugate vaccine

Total 6652 results

Sinovac Research and Development Co., Ltd.

Recruiting

A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

Pneumococcal Infectious Disease

China
Yale University
Gilead Sciences

Recruiting

A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

Cervical Cancer

United States
Korea University Guro Hospital
Merck Sharp & Dohme LLC

Not yet recruiting

Immunogenicity After Revaccination With 23-valent Pneumococcal Polysaccharide Vaccine: Healthy Elderly People Versus Diabetic Patients

Pneumococcal Infections

Korea, Republic of
VA Eastern Colorado Health Care System

Recruiting

Impact of HIV-1 and Aging on Mucosal Vaccine Responses

HIV Infections | HIV/AIDS | Human Immunodeficiency Virus | HIV-1-infection

United States
University of Witwatersrand, South Africa

Completed

Persistence of Immunogenicity Following Reduced PCV Dosing Schedules in South African Children (PCV1+1_FU)

Pneumonia | Meningitis

South Africa
argenx

Completed

Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV

Healthy Volunteers

Netherlands
Public Health England
Imperial College London; Institute of Child Health

Withdrawn

Assessment of Novel Pneumococcal Conjugate Vaccination Scheduled in UK Infants (PINC)

Vaccination | Immunization

United Kingdom
GlaxoSmithKline

Completed

Study to Evaluate the Response Rate to the Licensed Pneumovax 23™ in Elderly Population.

Streptococcus Pneumoniae Vaccines

Sweden
GlaxoSmithKline

Completed

Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.

Hepatitis B | Tetanus | Diphtheria | Haemophilus Influenzae Type b | Whole Cell Pertussis

Thailand
Novartis Vaccines
Novartis

Completed

Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.

Meningococcal Meningitis

Finland, Poland
Merck Sharp & Dohme LLC

Completed

A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)

Pneumococcal Disease
Korea University Guro Hospital
Pfizer

Completed

Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years

Influenza | Streptococcus Pneumoniae

Korea, Republic of
Emory University
National Cancer Institute (NCI); Sanofi; National Institutes of Health (NIH)

Completed

Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders

Plasma Cell Neoplasm

United States
Pfizer

Completed

Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13®

Pneumococcal Vaccines

Poland
MCM Vaccines B.V.

Completed

Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)

Virus Diseases | Bacterial Infections | Neisseria Meningitidis
Region Örebro County

Completed

Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia

Vaccine Response | CLL

Sweden
Merck Sharp & Dohme LLC

Completed

Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)

Pneumococcal Infection
University of Oxford
Mason Medical Research Trust

Completed

Pneumococcal Adult Kinetics Study - Understanding the B Cell Response to Pneumococcal Vaccines

Pneumococcal Disease

United Kingdom
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Active, not recruiting

Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months

Meningitis, Meningococcal

China
MCM Vaccines B.V.
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)

Virus Diseases | Bacterial Infections
Merck Sharp & Dohme LLC
MCM Vaccines B.V.

Completed

A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)

Virus Diseases | Bacterial Infections
GlaxoSmithKline

Completed

Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age

Measles | Rubella | Mumps | Varicella

United States
Butantan Institute

Completed

Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza (Xo_Gripe)

Influenza | Acute Respiratory Infection

Brazil
Region Skane
Lund University

Completed

Effects of Different Antirheumatic Treatments of Arthritis on Antibody Response Following Vaccination Using Prevenar® (PVA)

Rheumatoid Arthritis | Spondylarthropathy

Sweden
M.D. Anderson Cancer Center
Bayer

Completed

Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients

Leukemia

United States
International Vaccine Institute
Bill and Melinda Gates Foundation; SK Bioscience Co., Ltd.

Completed

Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)

Typhoid

Philippines
GlaxoSmithKline

Completed

Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

Australia
GlaxoSmithKline

Completed

Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age

Hepatitis A

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Toddlers

Meningitis | Meningococcal Infection

Australia
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico (MET33)

Healthy Volunteers (Meningococcal Infection)

Mexico, Russian Federation
International Vaccine Institute
SK Bioscience Co., Ltd.

Unknown

Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine

Typhoid

Nepal
Pfizer

Completed

Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults

Pneumococcal Disease

United States, Sweden
Novartis Vaccines
Novartis

Completed

Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants

Prevention of Meningococcal Disease

Canada, United Kingdom
Eunice Kennedy Shriver National Institute of Child...

Completed

Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants

Typhoid Fever

Vietnam
Pfizer

Completed

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan

Pneumococcal Disease

Korea, Republic of, Taiwan, Japan
Guy's and St Thomas' NHS Foundation Trust
National Institute for Health Research, United Kingdom

Active, not recruiting

Pneumococcal Vaccination to Accelerate Immune Recovery in Sepsis Survivors (VACIRiSS)

Sepsis

United Kingdom
National Institute of Allergy and Infectious Diseases...

Terminated

Antibody Production in Immune Disorders

Primary Immune Deficiency

United States
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)

Pneumococcal Infections
Uppsala University

Completed

Pneumococci and Hib Vaccination After Neurotrauma or Neurosurgery

Meningitis
GlaxoSmithKline

Terminated

Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children

Influenza

Norway
GPN Vaccines

Recruiting

Extension Safety and Immunogenicity Study of GPNV-001

Pneumococcal Infections

Australia
University of Maryland, Baltimore

Completed

Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease

Risk Reduction

United States
PT Bio Farma

Completed

Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants

Safety Issues | Immunogenicity

Indonesia
Region Skane

Completed

Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response (Vaccimil)

Syndrome | Vasculitis | SLE | Scleroderma | RA | Sjögrens

Sweden
GlaxoSmithKline

Completed

Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants.

Infections, Rotavirus
University of Oxford

Completed

Understanding the Immune Response to Two Different Meningitis Vaccines

Meningitis | Meningococcal Disease | Septicaemia

United Kingdom
GlaxoSmithKline
Affinivax, Inc.

Completed

A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine

Pneumonia, Bacterial | Healthy Volunteers | Pneumococcal Disease

United States
Pfizer

Completed

Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination

Pneumococcal Disease

United States, Sweden
University of Colorado, Denver
National Institute of Allergy and Infectious Diseases (NIAID)

Unknown

Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses

Pneumococcal Infections | HIV | Pneumococcal Vaccines

United States
Pfizer

Completed

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

Pneumococcal Infections

United States

3

Subscribe